BA vs PFE: Which Is the Better Buy?
Side-by-side comparison of The Boeing Company and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-22.
The Boeing Company · Industrials
$201.15
+31.7% upside to fair value
Med Conviction
Grade B
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
BA has more upside to fair value
(+31.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
BA |
PFE |
| Current Price |
$201.15 |
$27.64 |
| Fair Value Estimate |
$265.00 |
$30.94 |
| Upside to Fair Value |
+31.7%
|
+12.0%
|
| Market Cap |
$159.0B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
28.4x
|
17.4x
|
| Price / Sales |
1.7x
|
2.5x
|
| Price / FCF |
—
|
14.3x
|
| Revenue Growth YoY |
+8.0%
|
+2.6%
|
| Gross Margin |
4.7%
|
71.3%
|
| Operating Margin |
-5.4%
|
25.1%
|
| Return on Equity |
104.8%
|
4.9%
|
| Dividend Yield |
0% |
6.22% |
| FCF Yield |
—
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Boeing is a global aerospace and defense manufacturer spanning commercial airliners, military aircraft, satellites, missile defense, and aftermarket services, with roughly 182,000 employees and a business that remains structurally advantaged by the duopoly economics of large commercial aircraft and the long-cycle, high-switching-cost nature of aerospace platforms. The business quality is currentl…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
BA |
PFE |
| Zone Low |
$198.75 |
$23.21 |
| Zone High |
$225.25 |
$26.30 |
| In Buy Zone? |
Yes
|
No
|